8-K: Keros Therapeutics Halts PAH Program, Announces 45% Workforce Reduction Amid Strategic Review

Keros Therapeutics, Inc. has announced the discontinuation of its cibotercept program for pulmonary arterial hypertension (PAH) following disappointing Phase 2 trial results and a significant corporate restructuring involving a 45% workforce reduction, while continuing its strategic alternatives review.

Summary

• Keros Therapeutics has decided to discontinue all development of cibotercept (KER-012) in Pulmonary Arterial Hypertension (PAH) following the analysis of safety and efficacy data from its TROPOS Phase 2 clinical trial.
• The TROPOS trial was voluntarily halted early due to observations of pericardial effusions, with a dose-dependent signal seen for cibotercept, and no clinically meaningful improvement in pulmonary vascular resistance (PVR) or 6-minute walk distance (6MWD) was observed.
• In connection with this decision and an assessment of ongoing development programs, the company's Board of Directors approved a plan to reduce the overall workforce by approximately 45%, resulting in 85 full-time employees.
• The workforce reduction is expected to generate average annualized cost savings of approximately $17 million.
• Keros expects to incur one-time cash charges of approximately $3.2 million related to employee severance payments and related costs in the second quarter of 2025.
• Additionally, the company has committed to pay one-time employee retention costs of up to approximately $0.4 million, expected to be incurred through the fourth quarter of 2025.
• The reorganization is expected to be substantially complete by the fourth quarter of 2025.
• The Strategic Committee of the Board is continuing to evaluate a comprehensive range of strategic alternatives, including a sale of the company, other business combination, continued investment in the pipeline, and/or return of excess capital to stockholders.
• Keros intends to provide a preliminary update regarding the status of the strategic alternatives process no later than June 9, 2025.
• The company maintains a robust balance sheet and is making progress on its other development programs, including KER-065 for neuromuscular diseases (e.g., Duchenne muscular dystrophy) and elritercept (KER-050) for cytopenias in myelodysplastic syndrome and myelofibrosis.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the complete discontinuation of a key clinical program (cibotercept in PAH) following safety issues and lack of efficacy, leading to a significant workforce reduction. While cost savings and a strategic review are underway, the immediate news reflects a major pipeline setback and operational contraction.

Positives

• The corporate restructuring is expected to realize average annualized cost savings of approximately $17 million.
• Keros maintains a robust balance sheet, providing financial stability.
• The company is making meaningful progress on its other development programs, KER-065 and elritercept (KER-050).
• The Board is actively evaluating a comprehensive range of strategic alternatives to maximize value for all stockholders, including potential sale or return of excess capital.

Negatives

• Keros has discontinued all development of cibotercept (KER-012) in Pulmonary Arterial Hypertension (PAH) due to safety concerns and lack of efficacy.
• The TROPOS Phase 2 clinical trial for cibotercept was halted early due to observations of dose-dependent pericardial effusions.
• No clinically meaningful improvement in primary (PVR) or key secondary (6MWD) endpoints was observed for cibotercept in the TROPOS trial.
• The company is implementing a significant workforce reduction of approximately 45%, impacting employees.
• One-time cash charges of approximately $3.2 million for severance and $0.4 million for retention costs are expected due to the reorganization.

Risks

• The company may not be able to implement the Reorganization as currently anticipated or within the timing currently anticipated.
• The Reorganization could have an adverse impact on the company's business operations and employee morale.
• The company's cost saving initiatives may not be successful in achieving the anticipated financial benefits.
• Unanticipated charges or cash expenditures not currently contemplated may occur in connection with the implementation of the Reorganization.
• There is a risk that the objectives of the strategic alternative review process may not be achieved.
• The terms, structure, benefits, and costs of any potential strategic transaction are uncertain, and a transaction may not be consummated at all.
• The strategic alternatives review and workforce reduction could adversely affect the company's ability to retain and hire key personnel and maintain relationships with partners, suppliers, employees, and stockholders.
• The strategic alternatives review could divert the attention and time of the company's management.
• There is a risk of unexpected costs or expenses, or litigation, resulting from the strategic review or workforce reduction.
• Keros has a limited operating history and historical losses, which may impact its future viability.
• The company's ability to raise additional funding to complete the development and commercialization of its product candidates is uncertain.
• Keros is dependent on the success of its remaining product candidates, KER-065 and elritercept.
• Keros may be delayed in initiating, enrolling, or completing any future clinical trials.
• The company faces competition from third parties developing products for similar uses.
• Keros's ability to obtain, maintain, and protect its intellectual property is crucial for its success.
• The company is dependent on third parties in connection with manufacturing, clinical trials, and preclinical studies.

Future Outlook

Keros Therapeutics expects to incur approximately $3.2 million in one-time cash charges for severance in Q2 2025 and up to $0.4 million in employee retention costs through Q4 2025, with the reorganization substantially complete by Q4 2025. The company anticipates realizing average annualized cost savings of approximately $17 million from the workforce reduction. Keros plans to submit more detailed findings from the TROPOS trial at a future medical meeting and will evaluate the development strategy for cibotercept in other indications after completing its strategic alternative review. A preliminary update on the strategic alternatives process is expected by June 9, 2025, as the company focuses on executing its strategy for other development programs and maximizing stockholder value.

Management Comments

• Jasbir S. Seehra, Ph.D, Chair and Chief Executive Officer, stated: "Additional treatment options for individuals with PAH are critically needed. We are immensely grateful to the patients, investigators and Keros colleagues for their dedication to seeking new treatment options for this devastating disease."
• Dr. Seehra also commented: "Consistent with our commitment to being data driven and taking action to best position Keros to drive sustainable stockholder value, we have identified opportunities to restructure our operations and reduce costs as we focus on our key ongoing development programs. As a result, we have made the difficult decision to reduce our workforce to better align with our strategic priorities. We appreciate the hard work and dedication of our impacted team members and we are committed to supporting them through this transition. Looking ahead, Keros maintains a robust balance sheet and we are making meaningful progress on our other development programs. Our focus remains on the execution of our strategy as we concurrently work to complete the ongoing review of strategic alternatives to maximize value for all stockholders."

Industry Context

Pulmonary Arterial Hypertension (PAH) remains a debilitating disease with a 5-year survival rate only slightly above 50%, highlighting a critical unmet medical need for additional treatment options. The TGF-beta superfamily of proteins is recognized as a key pathway in PAH, with a third-party Phase 3 clinical trial of sotatercept demonstrating its importance. Keros's cibotercept was designed to modulate this pathway, similar to other investigational therapies in the space.

Comparison to Industry Standards

• The background rate of pericardial effusions observed in the placebo arm of the TROPOS trial (10% incidence) was noted to be higher than those seen in randomized, controlled trials of sotatercept, such as those referenced in New England Journal of Medicine publications by Humbert M et al. (2021) and Hoeper M et al. (2023).
• The maximum dose of sotatercept in PAH clinical trials was limited to 0.7 mg/kg due to increased hemoglobin observed in earlier-phase clinical trials, whereas cibotercept was evaluated at doses up to 4.5 mg/kg.

Corporate Governance

Legal Proceedings

• The company acknowledges the risk of any litigation relating to the strategic alternatives review or the workforce reduction.

Stakeholder Impact

• Shareholders: Potential for value maximization through the strategic review, but immediate negative impact from program discontinuation and workforce reduction.
• Employees: Approximately 45% of the workforce will be impacted by layoffs, with the company committing to support them through the transition, including severance and retention payments.
• Patients: The discontinuation of cibotercept in PAH means a potential new treatment option for this devastating disease will no longer be pursued by Keros.
• Investigators and Site Staff: Their dedication to the TROPOS trial was acknowledged, but the trial's early termination impacts their ongoing work.

Next Steps

• Submit more detailed findings from the TROPOS trial at a future medical meeting.
• Further evaluate the appropriate development strategy for cibotercept, if any, in other indications following the completion of the strategic alternative review process.
• Complete the ongoing review of strategic alternatives to maximize value for all stockholders.
• Provide a preliminary update regarding the status of the strategic alternatives process no later than June 9, 2025.
• Focus on the execution of the strategy for other ongoing development programs (KER-065 and elritercept).

Key Dates

Recommendation

Keywords

Keros Therapeutics, KROS, Biopharmaceutical, Pulmonary Arterial Hypertension, PAH, Cibotercept, KER-012, TROPOS trial, Workforce reduction, Corporate restructuring, Strategic review, Clinical trial results, Pericardial effusion, TGF-beta, Duchenne muscular dystrophy, Myelodysplastic syndrome, Myelofibrosis, Clinical-stage